Patients should always seek the advice of a doctor or pharmacist in case of adverse events.
If you wish to report an adverse event to ELC Group s.r.o., please find the contact information below:
To contact us about any other issue please call:
Pacienti by meli vždy požádat o radu svého lékare nebo lékárníka v prípade výskytu nežádoucích príhod.
Pokud chcete nahlásit nežádoucí príhodu spolecnosti ELC Group s r.o., prosím využijte kontaktních údaju níže:
Pro záležitosti, které se netýkaji farmakovigilance, kontaktujte prosím recepci:
+420 22 491 0000 nebo naše další pobočky.
Many of ELC’s 150 professionals have worked in the same industries that we deal with on a daily basis. Their experience and “insider knowledge” is invaluable for our clients as it enables us to achieve the necessary tasks in the most efficient, cost-effective way possible.
For the Pharmaceutical and the Medical Device divisions, ELC experts and project managers collaborate with 160 external collaborators (among which many ex-assessors from the national competent authorities and local experts in regulation requirements), allowing us to cater to different needs while optimising costs.
Concerning the Translation division, we do work with several hundreds of translators and proofreaders.
All of our projects are carefully managed by experienced project managers to ensure expedited project results without sacrificing quality.
We understand the importance of keeping the channels of communication open with our clients. This means we keep them informed every step of the way and we welcome their input and participation.
Some projects involve taking a product from development all the way through to commercialisation, others require only specialised attention in certain areas. No matter the nature or scale of a project, our commitment to quality remains the same.
ELC’s leadership makes a concerted effort to stay abreast of all current industry trends and innovations. If there is a better way to do things, we will a) know about it and b) put it into practice as quickly as possible.
Over the last 15 years, ELC has experienced significant growth and transformation. We started as a translation pure-player company, and soon after we entered the pharmaceutical market, we moved to the medical device and chemical ones as well. We learnt to adapt fast to new challenges, new industries and new requirements, we have been continuously growing and covering new activities.
In the pharmaceutical industry, for example, we have been one of the first organisations to bring non-EU companies into the EU market by assisting them with the new EU regulations for drug registrations.
We also recognised the complex difficulties faced by our clients in the area of pharmacovigilance (PV) which led to us offering PV services in 2010. As the industry has developed, vertical integration has proved necessary, which is one of the reasons ELC has expanded into formulation development.
2018-19 was a period of major restructuring within the company which has resulted in improved processes (refined and streamlined) and increased efficiency.
We will continue to adapt and grow in any way necessary to meet the demands of our clients.
With six offices in five countries around the world (Czech Republic, India, Romania, UK, US) ELC is currently partnering with over 500 clients in more than 60 countries.
